Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2016

View Archived Issues

Benitec to terminate HCV program

Novel sulfiredoxin inhibitor induces selective death of cancer cells

Lumosa Therapeutics describes novel thrombolytic agent DC-009

EMA committee recommends approval of Idelvion for hemophilia B

Innovate licenses larazotide acetate from Alba Therapeutics

Novel anti-HIV combinectin BMS-986197 may have enhanced resistance profile

Cebranopadol demonstrates significant improvements in lower backpain in phase IIb study

Siemens to release genetic assay for early detection of Zika virus

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents TLR7 agonists

Hydra Biosciences reports development of TRPC5 antagonists

FLAG-003 awarded E.U. orphan drug designation for glioma

MAA submitted for tivozanib as first-line treatment of advanced RCC

Z53 Therapeutics is launched as a novel oncology start-up

Modified version of troponin C modulates cardiac contractility in vivo

Preclinical and phase I results presented for HIV treatment/prophylaxis candidate MK-8591

Polymorphism in galectin-3 lectin domain is associated with beta-lactam allergy

Aytu BioScience and Hybridyne enter study agreement for trial using ProxiScan and ProstaScint

Pfizer initiates phase I study of PF-06801591

FDA approves Odefsey single-tablet regimen for HIV-1 infection

FDA announces new Orphan Products Natural History Grants program

Horizon Discovery and Centauri Therapeutics form Avvinity Therapeutics

Evgen cleared to begin phase II trial of SFX-01 for aneurysmal subarachnoid hemorrhage

ProStrakan signs agreement to acquire Moventig rights in Europe

FDA grants orphan drug designation to BMN-270 gene therapy for hemophilia A

New phase II trial investigates sulfatinib for thyroid cancer

First-in-human study of oral antimalarial drug SJ-733

Hikma closes acquisition of Roxane Laboratories and Boehringer Ingelheim Roxane

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...